Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26767657 | 0.84 | SLC6A2 (0.42) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL26645713 | 0.80 | PIK3CD (0.43) | SLC6A2SLC6A4PIK3CDSLC6A3NOS1 | |
| SCHEMBL2481382 | 0.79 | ADH1C (0.40) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL20780304 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL23733657 | 0.76 | SLC6A2 (0.43) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL24080142 | 0.76 | LTA4H (0.36) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9288887 | 0.76 | SLC6A2 (0.38) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL23943464 | 0.75 | — | — | |
| SCHEMBL18602764 | 0.75 | ADH1C (0.35) | — | |
| SCHEMBL19143811 | 0.74 | ADH1A (0.41) | SLC6A2SLC6A4PIK3CDSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | SLC6A2 1782/4885SLC6A4 1287/4885PIK3CD 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.